Group One Trading’s 9 Meters Biopharma NMTR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-10,363
Closed -$6.96K 8653
2023
Q2
$6.96K Buy
10,363
+5,000
+93% +$4.42K ﹤0.01% 6568
2023
Q1
$7.46K Sell
5,363
-6,009
-53% -$11.3K ﹤0.01% 6103
2022
Q4
$14.3K Buy
11,372
+1,815
+19% +$4.14K ﹤0.01% 5826
2022
Q3
$41K Sell
9,557
-802
-8% -$3.98K ﹤0.01% 5572
2022
Q2
$54K Buy
10,359
+7,100
+218% +$66.9K ﹤0.01% 5498
2022
Q1
$39K Sell
3,259
-6,943
-68% -$94.8K ﹤0.01% 6304
2021
Q4
$200K Sell
10,202
-13,567
-57% -$303K ﹤0.01% 5088
2021
Q3
$618K Buy
23,769
+8,314
+54% +$196K ﹤0.01% 3963
2021
Q2
$340K Buy
15,455
+7,844
+103% +$193K ﹤0.01% 4655
2021
Q1
$178K Buy
+7,611
New +$234K ﹤0.01% 5144
2020
Q4
Sell
-1,996
Closed -$33.3K 7175
2020
Q3
$33K Buy
+1,996
New +$24.2K ﹤0.01% 4894
2020
Q2
Sell
-243
Closed -$2.74K 6334
2020
Q1
$2K Hold
243
﹤0.01% 5023
2019
Q4
$3K Buy
+243
New +$4.05K ﹤0.01% 4859
2019
Q1
Sell
-389
Closed -$16.8K 5521
2018
Q4
$18K Sell
389
-90
-19% -$6.67K ﹤0.01% 4071
2018
Q3
$65K Buy
+479
New +$82.3K ﹤0.01% 3819

Other funds holding NMTR

Group One Trading's NMTR Position: Q3 2023 in Review

Group One Trading sold out of 9 Meters Biopharma (NMTR) in Q3 2023, closing a stake of 10,363 shares — an estimated $6.96K sold.

Group One Trading first reported a position in NMTR in Q3 2018 and held it in 15 quarters. The position peaked at $618K in Q3 2021. 6 funds tracked by Wall St. Rank hold NMTR as of Q3 2023.

  • Group One Trading reported no remaining 9 Meters Biopharma position as of Q3 2023 after selling out during the quarter.
  • Group One Trading sold 10,363 9 Meters Biopharma shares in Q3 2023, an estimated $6.96K.
  • Group One Trading first reported a position in 9 Meters Biopharma in Q3 2018 and held it in 15 quarters.
  • Group One Trading's 9 Meters Biopharma position peaked at $618K in Q3 2021.
  • 6 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q3 2023.

Based on Group One Trading's 13F filing for Q3 2023, filed 9 Nov 2023.